Cardiac Development and Hypertrophy

Dr. Schneider is a recipient of grants from the National Institutes of Health (ROl HL39141, RO1 HL47567) and a Grant-in-Aid (91-009790) and Established Investigator Award from the American Heart Association. He is also an investigator of the National Heart, Lung, and Blood Institute Specialized Center of Research in Heart Failure (P50 HL42267) and co-director of the National Heart, Lung, and Blood Institute Training Center in Molecular Cardiology (T32 HL07706). Dr. MacLellan is a Fellow of the Medical Research Council of Canada and the American Heart Association-Bugher Foundation Center for Molecular Biology of the Cardiovascular System. Dr. Kirshenbaum is a Fellow of the Medical Research Council of Canada. Dr. Brand is a Fellow of the Deutsche Forschungsgemeinschaft.

[1]  T. Brand,et al.  Transforming growth factor-beta in cardiac ontogeny and adaptation. , 1993, Circulation research.

[2]  B. A. French,et al.  Highly efficient gene transfer into adult ventricular myocytes by recombinant adenovirus. , 1993, The Journal of clinical investigation.

[3]  T. Brand,et al.  A dominant-negative receptor for type beta transforming growth factors created by deletion of the kinase domain. , 1993, The Journal of biological chemistry.

[4]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Rudnicki,et al.  Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development , 1992, Cell.

[6]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[7]  D. Melton,et al.  A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos , 1992, Nature.

[8]  F. Villarreal,et al.  Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. , 1992, The American journal of physiology.

[9]  R. Schwartz,et al.  Positive and negative control of the skeletal alpha-actin promoter in cardiac muscle. A proximal serum response element is sufficient for induction by basic fibroblast growth factor (FGF) but not for inhibition by acidic FGF. , 1992, The Journal of biological chemistry.

[10]  M. Kirschner,et al.  Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in xenopus embryos , 1991, Cell.

[11]  H. Ueno,et al.  Inhibition of PDGF beta receptor signal transduction by coexpression of a truncated receptor , 1991, Science.

[12]  R. Schwartz,et al.  Differential regulation of skeletal alpha-actin transcription in cardiac muscle by two fibroblast growth factors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Parker,et al.  Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. , 1990, The Journal of clinical investigation.

[14]  J. Massagué.  Receptors for the TGF-beta family. , 1992, Cell.

[15]  T. Parker,et al.  Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. , 1991, Annual review of physiology.

[16]  T. Parker,et al.  Cardiac growth factors. , 1991, Progress in growth factor research.